Blog
Elevance Health Q2 Earnings Call Highlights
Key Points
- Interested in Elevance Health, Inc.? Here are five stocks we like better.
- Elevance Health raised its 2026 adjusted EPS outlook after Q2 results beat expectations, now guiding to at
Alphabet’s AI Spending Question Looms Over Q2 Earnings
Key Points
- Interested in Alphabet Inc.? Here are five stocks we like better.
- Alphabet's Q2 2026 report, due July 22, is considered pivotal given the stock trades roughly 12% below its 52-week
3 Small-Cap Stocks Trading Under $10 With Room to Run
Key Points
- Interested in Aveanna Healthcare Holdings Inc.? Here are five stocks we like better.
- As mega-cap tech stumbles, analyst James Early recommends Aveanna Healthcare, Genworth Financial
CleanSpark Inks a $6.6B AI Lease to Become a Digital Landlord
Key Points
- Interested in Cleanspark, Inc.? Here are five stocks we like better.
- CleanSpark signed a $6.6 billion, 20-year triple-net lease in Sandersville, Georgia, providing 175 megawatts to an
M&T Bank Q2 Earnings Call Highlights
Key Points
- Interested in M&T Bank Corporation? Here are five stocks we like better.
- M&T Bank posted a record second quarter, with diluted EPS of $5.32 and net income of $818 million, helped by
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women
Key Points
- Interested in Veradermics, Incorporated? Here are five stocks we like better.
- Veradermics reported a strong phase II signal for its oral hair-loss drug VDPHL01 in women, with
Morgan Stanley Q2 Earnings Call Highlights
Key Points
- Interested in Morgan Stanley? Here are five stocks we like better.
- Record second-quarter results: Morgan Stanley reported revenue of $21.3 billion and EPS of $3.46, with management
Johnson & Johnson Q2 Earnings Call Highlights
Key Points
- Interested in Johnson & Johnson? Here are five stocks we like better.
- Johnson & Johnson raised its full-year 2026 outlook after reporting a Q2 beat on both revenue and earnings
Sify Technologies Q1 Earnings Call Highlights
Key Points
- Interested in Sify Technologies Limited? Here are five stocks we like better.
- Sify Technologies reported strong Q1 fiscal 2026-27 results, with revenue up 15% year over year to INR
3 Gold Stocks Under $5 With Massive Upside
Key Points
- Interested in Gold Royalty Corp.? Here are five stocks we like better.
- Central banks purchased 474 tons of gold in Q1 2026, and nearly 90% plan to keep increasing reserves over the
Blueprint for a Billion: Nebius Group Secures the AI Floor
Key Points
- Interested in Nebius Group N.V.? Here are five stocks we like better.
- Nebius Group's stock dropped roughly 6% on 15 million shares traded as macroeconomic concerns triggered a broad
BlackRock Q2 Earnings Call Highlights
Key Points
- Interested in BlackRock? Here are five stocks we like better.
- BlackRock posted record Q2 results, with revenue up 31% to $7.1 billion, adjusted operating income up 39% to $2.9
Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s
Key Points
- Interested in Fractyl Health, Inc.? Here are five stocks we like better.
- Fractyl Health said its Revita procedure helped patients keep more of their GLP-1-driven weight loss after
Conagra Brands Q4 Earnings Call Highlights
Key Points
- Interested in Conagra Brands? Here are five stocks we like better.
- Conagra Brands said fiscal Q4 and full-year results were within its original guidance, but sales were flat and
As the Iran War Resumes, 2 Energy ETFs Ride Oil’s Renewed Rally
Key Points
- Interested in iShares Global Energy ETF? Here are five stocks we like better.
- Renewed U.S.-Iran hostilities and Strait of Hormuz tensions have driven Brent crude prices up more than
Gore Street Energy Storage Fund H2 Earnings Call Highlights
Key Points
- Interested in Gore Street Energy Storage Fund? Here are five stocks we like better.
- Net asset value fell sharply to 74.9p from 102.8p, driven mainly by revised revenue forecasts in
Tower Semiconductor’s AI Rally Is Built on a Light-Speed Bet
Key Points
- Interested in Tower Semiconductor Ltd.? Here are five stocks we like better.
- Tower Semiconductor shares rose more than 13% after announcing a $3 billion dual-track expansion in Japan
Marriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade
Key Points
- Interested in Marriott International, Inc.? Here are five stocks we like better.
- U.S. tourism spending hit roughly $1.35 trillion in 2025, with baby boomers outspending other
Barratt Redrow Q4 Earnings Call Highlights
Key Points
- Interested in Barratt Redrow plc? Here are five stocks we like better.
- Barratt Redrow reported a solid FY 2026, with completions up 5% to 17,667 homes and adjusted profit before tax
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer
Key Points
- Interested in Celcuity, Inc.? Here are five stocks we like better.
- Celcuity won full FDA approval for gedatolisib, now branded REVTORPYK, in a specific advanced breast cancer
ASML Q2 Earnings Call Highlights
Key Points
- Interested in ASML Holding N.V.? Here are five stocks we like better.
- ASML beat second-quarter guidance with net sales of EUR 9.3 billion and a 54% gross margin, helped by
Aehr Test Systems Q4 Earnings Call Highlights
Key Points
- Interested in Aehr Test Systems? Here are five stocks we like better.
- Aehr Test Systems entered fiscal 2027 with a record backlog and raised revenue guidance to $130 million to $150
Phoenix Education Partners Q3 Earnings Call Highlights
Key Points
- Interested in Phoenix Education Partners, Inc.? Here are five stocks we like better.
- Q3 revenue was essentially flat at $271.8 million, but profit fell as Phoenix Education Partners
Kestra Medical Technologies Q4 Earnings Call Highlights
Key Points
- Interested in Kestra Medical Technologies, Ltd.? Here are five stocks we like better.
- Revenue surged in Q4, with Kestra posting $28.6 million in revenue, up 66% year over year
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
Key Points
- Interested in Syndax Pharmaceuticals, Inc.? Here are five stocks we like better.
- Syndax Pharmaceuticals is broadening its growth plan beyond Revuforj and Niktimvo, highlighting new